ArticleMycopathologia2011
Antifungal activity of antifungal drugs, as well as drug combinations against Exophiala dermatitidis.
Article in Mycopathologia, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- A fatal neonatal case of fungemia due to Exophiala dermatitidis-case report and literature review.BMC pediatrics · 2022Pooled it
- Bronchobiliary fistula secondary to hepatic malignancy with Exophiala dermatitidis infection: a case report.BMC infectious diseases · 2026Article
- Pulmonary Chromomycosis Caused by Exophiala phaeomuriformis in a Patient with a Typical Pulmonary Carcinoid Tumor.Internal medicine (Tokyo, Japan) · 2025Article
- Antifungal Susceptibility of Melanized Fungi Isolated from CARD9 Deficient Patients: Implications for Treatment of Refractory Infections.Mycopathologia · 2025Article
- Diverse antifungal potency of terbinafine as a therapeutic agent against Exophiala dermatitidis in vitro.Scientific reports · 2024Article
- Cerebral phaeohyphomycosis at a tertiary healthcare center in Saudi Arabia.Neurosciences (Riyadh, Saudi Arabia) · 2023Article
- Exophiala dermatitidis Central Line-Associated Bloodstream Infection in a Child with Ewing's Sarcoma: Case Report and Literature Review on Paediatric Infections.Mycopathologia · 2022Review
- Article
- Article
- Exophiala dermatitidis Fungemia Diagnosed Using Time-of-flight Mass Spectrometry during Chemotherapy for Malignant Lymphoma and Successful Treatment with Voriconazole.Internal medicine (Tokyo, Japan) · 2019Article
- Invasive Fungal Infection Caused by Exophiala dermatitidis in a Patient After Lung Transplantation: Case Report and Literature Review.Mycopathologia · 2019Review
- Disseminated Exophiala dermatitidis causing septic arthritis and osteomyelitis.BMC infectious diseases · 2018Article
- Combination of Amphotericin B and Terbinafine against Melanized Fungi Associated with Chromoblastomycosis.Antimicrobial agents and chemotherapy · 2018Article
- Combination of Amphotericin B and Flucytosine against Neurotropic Species of Melanized Fungi Causing Primary Cerebral Phaeohyphomycosis.Antimicrobial agents and chemotherapy · 2016Article
- A rare case report of subcutaneous phaeohyphomycotic cyst caused by Exophiala oligosperma in an immunocompetent host with literature review.Mycopathologia · 2014Review
- Drug combinations against Mucor irregularis in vitro.Antimicrobial agents and chemotherapy · 2013Article
- In vitro susceptibility of environmental isolates of Exophiala dermatitidis to five antifungal drugs.Mycopathologia · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the in vitro efficacy of common antifungal drugs, as well as the interactions of caspofungin with voriconazole, amphotericin B, or itraconazole against the pathogenic black yeast Exophiala dermatitidis from China, the minimal inhibitory concentrations (MICs) of terbinafine, voriconazole, itraconazole, amphotericin B, fluconazole, and caspofungin against 16 strains of E. dermatitidis were determined by using CLSI broth microdilution method (M38-A2). The minimal fungicidal concentrations (MFCs) were also determined. Additionally, the interactions of caspofungin with voriconazole, amphotericin B, itraconazole or fluconazole, that of terbinafine with itraconazole, or that of fluconazole with amphotericin B were assessed by using the checkerboard technique. The fractional inhibitory concentration index (FICI) was used to categorize drug interactions as following, synergy, FICI ≤ 0.5; indifference, FICI > 0.5 and ≤4.0; or antagonism, FICI > 4.0. The MIC ranges of terbinafine, voriconazole, itraconazole, amphotericin B, fluconazole, and caspofungin against E. dermatitidis were 0.06-0.125 mg/l, 0.25-1.0 mg/l, 1.0-2.0 mg/l, 1.0-2.0 mg/l, 16-64 mg/l, and 32-64 mg/l, respectively. The in vitro interactions of caspofungin with voriconazole, amphotericin B, and itraconazole showed synergic effect against 10/16(62.5%), 15/16(93.75%), and 16/16(100%) isolates, while that of caspofungin with fluconazole showed indifference. Besides, the interaction of terbinafine with itraconazole as well as that of fluconazole with amphotericin B showed indifference. Terbinafine, voriconazole, itraconazole, and amphotericin B have good activity against E. dermatitidis. The combinations of caspofungin with voriconazole, amphotericin B or itraconazole present synergic activity against E. dermatitidis. These results provide the basis for novel options in treating various E. dermatitidis infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.